- Home
- CZNC vs DMAC Comparison
CZNC vs DMAC Comparison
Compare CZNC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- DMAC
- Stock Information
- Founded
- CZNC 1864
- DMAC 2000
- Country
- CZNC United States
- DMAC United States
- Employees
- CZNC N/A
- DMAC N/A
- Industry
- CZNC Major Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- DMAC Health Care
- Exchange
- CZNC Nasdaq
- DMAC Nasdaq
- Market Cap
- CZNC 301.8M
- DMAC 310.1M
- IPO Year
- CZNC N/A
- DMAC N/A
- Fundamental
- Price
- CZNC $20.20
- DMAC $5.71
- Analyst Decision
- CZNC
- DMAC Strong Buy
- Analyst Count
- CZNC 0
- DMAC 3
- Target Price
- CZNC N/A
- DMAC $12.33
- AVG Volume (30 Days)
- CZNC 49.3K
- DMAC 315.7K
- Earning Date
- CZNC 08-08-2025
- DMAC 08-12-2025
- Dividend Yield
- CZNC 5.54%
- DMAC N/A
- EPS Growth
- CZNC 15.34
- DMAC N/A
- EPS
- CZNC 1.75
- DMAC N/A
- Revenue
- CZNC $108,310,000.00
- DMAC N/A
- Revenue This Year
- CZNC $5.72
- DMAC N/A
- Revenue Next Year
- CZNC $7.18
- DMAC N/A
- P/E Ratio
- CZNC $11.57
- DMAC N/A
- Revenue Growth
- CZNC 4.96
- DMAC N/A
- 52 Week Low
- CZNC $17.85
- DMAC $3.19
- 52 Week High
- CZNC $22.68
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- CZNC 58.87
- DMAC 57.83
- Support Level
- CZNC $19.13
- DMAC $5.90
- Resistance Level
- CZNC $20.57
- DMAC $6.16
- Average True Range (ATR)
- CZNC 0.52
- DMAC 0.38
- MACD
- CZNC 0.11
- DMAC -0.03
- Stochastic Oscillator
- CZNC 78.36
- DMAC 61.02
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.